INS and metabolic dysfunction-associated steatotic liver disease: For early-stage MASLD patients dominated by metabolic dysregulation, a low-dose QHD regimen administered for 8 ~ 12 weeks may be sufficient to restore metabolic homeostasis, improve insulin sensitivity, and reduce hepatic fat accumulation.